Morningside Venture Investments Ltd's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Jan 25, 2022
- Accession no.
- 0000899243-22-003157
- Filed
- Jan 25, 2022
- Trade date
- Jan 11, 2022
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market purchases total $5.00M. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morningside Venture Investments LtdCIK 0001543112 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common Stock | CConversionAcquired | +10,415,650 | –F1 | – | 10,415,650 | Direct | |
| Jan 11, 2022 | Common Stock | PPurchaseAcquired | +263,158 | $19.00 | +$5,000,002 | 10,678,808 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common Stock | CConversionDisposed | −1,409,035 | $0.00 | $0 | 0 | Direct | |
| Jan 11, 2022 | Common Stock | CConversionDisposed | −6,410,964 | $0.00 | $0 | 0 | Direct | |
| Jan 11, 2022 | Common Stock | CConversionDisposed | −974,107 | $0.00 | $0 | 0 | Direct | |
| Jan 11, 2022 | Common Stock | CConversionDisposed | −1,621,544 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I.